UAB researchers reverse liver disease in mice with gene therapy

UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver disease associated with obesity and type 2 diabetes that affects more than 40 million people.

ABBV-400 by AbbVie for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

December 21, 2023

Healthy lifestyle can overcome genetic risk of obesity, new study reveals

Study demonstrates that adherence to a healthy lifestyle can significantly mitigate the genetic risk of obesity and its related morbidities, emphasizing the importance of promoting

July 4, 2024

GHIT Fund invests Y1.64bn in malaria and NTD drug development

Shionogi, Nagasaki University, the National Institute of Infectious Diseases and MMV are working on a malaria chemoprevention drug. Credit: namtipStudio/Shuttersttock.com. The Global Health Innovative Technology

May 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.